Related Experiment Video
Updated: Jun 1, 2026
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Monocyte chemoattractant protein-1 is associated with silent cerebral infarction in patients on haemodialysis
Insights
Monocyte chemoattractant protein-1 (MCP-1) is significantly associated with silent cerebral infarctions (SCI) in patients undergoing hemodialysis (HD). Higher MCP-1 levels predict SCI occurrence in this high-risk population.
Area of Science:
- Nephrology
- Neurology
- Biomarkers
Background:
- Silent cerebral infarctions (SCI) are common in patients with chronic renal failure on hemodialysis (HD) and linked to mortality.
- Monocyte chemoattractant protein-1 (MCP-1) levels rise with renal dysfunction, suggesting a role in cerebrovascular events.
Purpose of the Study:
- To investigate the correlation between elevated MCP-1 concentrations and the incidence of SCI in HD patients.
- To identify MCP-1 as a potential predictor for SCI in individuals with chronic kidney disease undergoing dialysis.
Main Methods:
- Cranial magnetic resonance imaging (MRI) identified SCI in 52 Japanese HD patients.
- Patients were categorized into groups with and without SCI for comparative analysis.
- Demographic, metabolic profiles, and MCP-1 levels were assessed.
Main Results:
- MCP-1 levels were significantly higher in patients with SCI compared to those without (P < 0.0001).
- The SCI group had a higher proportion of smokers and lower high-density lipoprotein cholesterol levels.
- Higher uric acid levels and MCP-1 were independently associated with SCI presence (OR 1.48, P < 0.0001).
Conclusions:
- Patients on HD for chronic renal failure have a high prevalence of SCI.
- MCP-1 is a significant independent predictor of SCI in the hemodialysis population.
- MCP-1 may serve as a valuable biomarker for assessing cerebrovascular risk in renal failure patients.
Background:
In patients with chronic renal failure undergoing haemodialysis (HD), silent cerebral infarctions (SCI) are associated with high mortality. Levels of monocyte chemoattractant protein-1 (MCP-1) increase with renal dysfunction and may be a novel predictor for cerebrovascular events. We tested the hypothesis that increased MCP-1 concentration correlate with the occurrence of SCI in HD patients.
Methods:
Using cranial magnetic resonance imaging (MRI) findings, 52 Japanese patients undergoing HD were divided into two groups: with SCI (61 ± 7 years, mean ± SD, n= 28) and without SCI (60 ± 6 years, n= 24). The gender, metabolic profiles and MCP-1 concentration were compared between the two groups.
Results:
The level of MCP-1 was higher in the with-SCI group than in the without-SCI group (P < 0.0001). The proportion of smokers was higher in the with-SCI group (P < 0.05) than in the without-SCI group. Plasma level of high-density lipoprotein cholesterol was lower, while uric acid level was higher, in the with-SCI group (P < 0.05 and P < 0.05 respectively) compared to the without-SCI group. Multiple logistic regression analysis identified MCP-1 level as being significantly associated with the presence of SCI (odds ratio 1.48, 95% confidence interval = 1.10-5.75, P < 0.0001).
Conclusions:
This study indicates that patients with chronic renal failure who are maintained on HD exhibit an increased prevalence of SCI, and that MCP-1 is significantly associated with the presence of SCI in HD patients.
More Related Videos
10:59Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
Published on: November 23, 2017
09:57Quantification of Monocyte Chemotactic Activity In Vivo and Characterization of Blood Monocyte Derived Macrophages
Published on: August 12, 2019